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Background: The choice of treatment in laryngeal cancer is mainly based on tumor 
stage, post-treatment morbidity and quality of life. Biological tumor markers might 
also be of potential clinical relevance.  
Objective of the review: The aim was to systematically review the value of published 
biological tumor markers to predict local control in laryngeal cancer patients treated 
with definitive radiotherapy. 
Type of Review: Systematic review. 
Search strategy: Pubmed, Embase, Cochrane Library.  
Evaluation Method: A literature search was performed using multiple terms for 
laryngeal cancer, radiotherapy, biological markers, detection methods and local 
control or survival. Studies regarding the relation between biological tumor markers 
and local control or survival in laryngeal cancer patients primarily treated with 
radiotherapy were included. Markers were clustered on biological function. Quality of 
all studies was assessed. Study selection, data extraction, and quality assessment was 
performed by two independent reviewers.  
Results: 52 studies out of 618 manuscripts, concerning 118 markers were included. 
EGFR and P53 showed consistent evidence for not being predictive of local control 
after primary radiotherapy, whereas proliferation markers (i.e. high Ki-67 expression) 
showed some, but no consistent, evidence for being predictive of better local control. 
Other clusters of markers (markers involved in angiogenesis and hypoxia, apoptosis 
markers, cell cycle, COX-2, DNA characteristics) showed no consistent evidence 









 This article is protected by copyright. All rights reserved 
Conclusions: Cell proliferation could be of potential interest for predicting local 
control after primary radiotherapy in laryngeal cancer patients, whereas EGFR and 
p53 are not predictive in contrast with some previous analyses. Large diversity in 
research methods is found between studies, which results in contradictory outcomes. 
Future studies need to be more standardized and well described according to the 
REMARK criteria in order to have better insight into which biomarkers can be used 





- This systematic review presents an overview of the value of all published 
biological tumor markers to predict local control in laryngeal cancer patients 
treated with definitive radiotherapy. 
- The data show that cell proliferation could be of potential interest for 
predicting local control in laryngeal cancer patients treated with primary 
radiotherapy.  
- EGFR and p53 are not predictive of local control after primary radiotherapy in 
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Introduction 
 
Worldwide, laryngeal cancer is diagnosed in 157.000 patients and is responsible for 
83.000 deaths each year.
1
 Treatment of laryngeal cancer is nowadays highly focused 
on laryngeal preservation, retaining the main functions of the of the larynx; speech, 
breathing and swallowing, with primary radiotherapy as one of the most important 
treatment modalities. Despite relatively early diagnosis and efforts to improve 
treatments, overall survival rates have not significantly improved over the last 30 
years.
2
 Currently, the choice of treatment in laryngeal cancer is mainly based on 
tumor stage, post-treatment morbidity and quality of life.
3
 Besides these 
clinicopathological and patient factors, biological tumor markers might be of potential 
clinical relevance. The aim of this systematic review was to identify predictive 
biological tumor markers that are relevant for the outcome of primary radiotherapy in 
laryngeal cancer. The main endpoint for outcome after primary radiotherapy was local 
control. Most common definitions for local control were: time to local disease-free 














A literature search was performed in Pubmed, Embase, and in the Cochrane Library 
on July 19
th
 2018, to identify studies on predictive biological tumor markers in 
laryngeal cancer patients primarily treated by radiotherapy. The search was updated 
on May 23
th
 2019. An extensive search was performed using keywords as well as free 
search terms on the following items: 1) laryngeal cancer; 2) radiotherapy or 
chemoradiation; 3) biological tumor markers or common detection methods used in 
prognostic marker studies; and 4) prognosis or response. The final search strategy 
used is shown in Supplementary Table 1 (S1). 
 
Selection criteria 
A title, abstract and finally manuscript selection was performed, using the following 
exclusion criteria: 1) non-English articles; 2) tumor site other than larynx; 3) 
treatment modalities other than primary radiotherapy; 4) markers not studied in 
primary tumor tissue e.g. serum tumor markers; 5) no biological tumor marker 
studied; 6) outcome other than radiotherapy response or locoregional recurrence 
reported; 7) cell lines or xenograft models; and 8) non-original research articles e.g. 
reviews, case reports. Title, abstract and manuscript selection, as well as data 




From the papers included in this systematic review the following data was extracted 
and recorded in a predefined database: 1) year of publication; 2) number of patients; 
3) retrospective or prospective patient selection; 4) patient’s characteristics: age, 
gender, stage, location; 5) details on radiotherapy; 6) details on the assay used: assay 
method, cut-offs, number of positive and negative tumors; 7) results of the analysis to 
evaluate the relation between the marker and outcome of radiotherapy. This could be 
either results of survival analysis for local disease-free survival (log-rank analysis, 
Cox regression) or, in case of a matched-control study results of the chi-square test, 
logistic regression analysis, T-test, or Mann-Whitney U test. Biological tumor 
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Study quality 
Study quality assessment was based on the REMARK (REporting recommendations 
for tumor MARKer prognostic studies) criteria from McShane et al.
4
 A comparable 
quality measurement form was used previously in a systematic review.
5
 In short, the 
following items were explored: 1) four out of six of the following patient and tumor 
characteristics were described: age, gender, tumor location, T-stage, N-stage, 
differentiation grade; 2) the study reported inclusion and exclusion criteria; 3) the 
radiotherapy treatment schedule was well described; 4) definition of the study 
endpoint was given; 5) the relation between marker and outcome was sufficiently 
described; 6) a rational for number of patient tested was given; 7.1) the assay used to 
measure biomarker expression was sufficiently described, 7.2) as well as 
interpretation of the assay; 8) the follow-up time of patients in the study was 
described; 9) the study reported how many patients were available for statistical 
analysis; 10) limitations of the study were described. A maximum of 11 points could 




Results of the analysis describing the relation between a marker and local control after 
radiotherapy were compared. P-values of <0.05 were considered statistically 
significant. P-values of <0.10 were considered as a trend (explicitly stated).  
A biological tumor marker was considered as a potential marker for local control if 
>50% of the studies investigating the marker described a relation with either poor or 
good local control after radiotherapy. In case the study results were sufficiently 
described in the manuscript, but only a P-value was presented, the Odds ratio (OR) 
and 95% Confidence Interval (CI) were calculated (explicitly stated).
6
 This enabled us 
to compare results of various studies reporting on the same biological tumor marker 
better. Also, to uniformly present the data, ‘positive’ expression is used as indicator; 
in case a manuscript presented the results with ‘negative’ expression as indicator, we 
inverted the OR or Hazard Ratio (HR) and 95%CI. 
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The data that support the findings of this study are available from the corresponding 
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Results 
 
In total, 400 (English n=359) manuscripts were identified in Pubmed, and 435 
(English n=427) in Embase. No Cochrane review was available. After removal of 
duplicate publications, 651 were further analyzed. Figure 1 shows a flow chart of 
selection process. Finally, 52 studies describing 118 markers could be included. 
Remarkably, all of the included studies were identified in Pubmed, no additional were 
found in Embase.  
 
Study characteristics and study quality 
In total 52 studies concerning 118 biological tumor markers were included. Studies 
had been published between 1987 and 2017 (median 2007). A maximum of 13 
markers was investigated by one study. The median number of patients per study 
included was 60 (range 21-281). The median quality score was 6 out of 11 (range 3-
10). A low number of studies reported in- and exclusion criteria and none of the 
studies gave a rational for the number of patients analyzed (power analysis). This is 
due to the retrospective design of most studies. Patient characteristics and details of 
the assay used were generally described well (50 of 52 studies). Studies published 
from 2007 (median 7, range 4-10) were of better quality than studies published before 
2007 (median 6, range 3-8) (P=0.03).  
 
Proliferation 
Ki-67, a nuclear protein involved in cell proliferation, was described eleven times 
(Table 1). In five, high Ki-67 proliferation index was related to better local control 
after radiotherapy (two out of five showed a trend, studies with low number of 
patients), either in uni- or multivariate analysis.
7-11
 In four, no relation with local 
control was found.
12-15
 Also, in two other papers an inverse correlation was found; 
high Ki-67 expression being a predictor for poor local control.
16,17
 Interestingly, in the 
paper of Sakata et al. the association with local recurrence was only found in patients 
treated by accelerated radiotherapy, not in the group treated by conventional 
radiotherapy.
17
 Another marker for proliferation is Proliferating Cell Nuclear Antigen 
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PCNA expression (Table 1),
18
 again indicating that high proliferation contributes to 
good outcome after radiotherapy. 
 
Angiogenesis and hypoxia 
Eight studies investigating five angiogenesis or hypoxia associated markers were 
included (Table S2). Hypoxia-inducible factor 1α (HIF-1α) was found to be a 
predictor of poor outcome after radiotherapy in two out of five studies.
12,14,19-21
 
Hypoxia also induces CA-IX expression in tumor cells. Two out of six studies 
investigating CA-IX showed that positive expression predicted poor local control after 
radiotherapy.
12,14,19-22
 Glucose transporter 1 (Glut-1), Osteopontin (OPN), and 
vascular endothelial growth factor (VEGF) were not associated with outcome after 
radiotherapy.
12,19,21,23,24






Apoptotic marker BCL-2 was studied most extensively and expression was associated 
with local recurrence in two out of seven studies.
14-16,20,26-28
 Bxl-xL showed a relation 
with poor local control in one study,
14,27
 while Bax was associated with favorable 
outcome in one out of three studies.
15,27,28
 Bak, Survivin, and BAG-1 were studied 
once, and only BAG-1 showed a trend towards poor local control.
27,29
 (Table S3).  
 
P53 
The human tumor suppressor gene p53 was investigated extensively; fourteen studies 
found no relation with local control.
8-11,14,15,23,28,30-35
 Only Narayana et al. found poor 
local control in glottic carcinomas
36
 (Table S4). Overall suggesting p53 not as a 
relevant marker for local control after radiotherapy. 
 
Cell cycle 
FADD was not associated with local control, whereas phosphorylated FADD only 
showed a relation with better local control in glottic tumors, but not in supraglottic 
tumors.
37,38
 Cyclin D1 showed some contradictory results; three out of five studies did 
not show a relation, while Yoo et al. found cyclin D1 to be a predictor for better local 
control and Chang et al. for poor local control after radiotherapy.
7,14,37,39,40
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(both three studies) and p27 showed no relation with local control, as well as 
retinoblastoma gene (Rb)
14,15,30,32,41
 (Table S5). 
 
COX-2 
Cyclooxygenase-2 (COX-2) was described four times (Table S6), two studies showed 
a relation between positive expression and poor local control, in either univariate of 
multivariate analysis,
10,42





The epidermal growth factor receptor (EGFR) is a well-known and extensively 
studied biological tumor marker. Protein expression of EGFR in relation with local 
control after radiotherapy in laryngeal cancer patients has been studied in ten 
independent studies (Table S7).
7,8,14,16,23,26,39,43-45
 Only Miyaguchi et al. found a 
relation between positivity of EGFR and recurrence,
45
 thereby concluding EGFR is 
not a relevant marker.  
 
DNA content 
Seven, mostly older studies (6 of 7 <=1995), investigated DNA ploidy and compared 
diploid with aneuploid tumors. Three found no relation with local control, while 
Toffoli et al. found that diploid tumors showed poor local control and three others 




Genome wide expression profiling 
Instead of analyzing individual, mostly well-known, and frequently investigated 
biological tumor markers, it is also possible to perform genome wide expression 
profiling for example by using mRNA expression microarrays. One study using gene 
expression data to discover markers for radiotherapy outcome in laryngeal cancer was 
identified. De Jong et al. studied 52 laryngeal cancer patients with or without a local 
recurrence after radiotherapy.
52
 Expression of the stem cell associated marker CD44 
showed a relation with local recurrence (HR 20.2, 95%CI 3.4-172.3), and this was 
confirmed by immunohistochemistry for CD44 in an independent set of 76 laryngeal 
cancer patients (HR 15.2, P<0.01). However, gene sets defining hypoxia, 
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Micro-RNAs 
Micro-RNAs were investigated by two (Table S9). Maia et al. found miR-296-5p 
associated with poor locoregional control and de Jong et al. found miR-203 as 




Miscellaneous biological tumor markers 
An overview of the predictive value of other markers is given in Table S10. All of 
these markers were studied once. ATM, LOH at 9p21, LOH at 3p21, BCCIP, 
Cortactin, ERCC1, and EPOR were not predictive of outcome,
12,15,21,28,31,55
, whereas 
EpCAM/BerEP4, IGF-1R, HDAC1, NF-κB, 1 integrin, and TGF-α were associated 
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Discussion 
 
Summary of main results 
In this systematic review a comprehensive overview of studies reporting on biological 
tumor markers in relation to local control after primary radiotherapy in laryngeal 
cancer patients is presented. None of the investigated markers or clusters of markers 
showed consistent evidence for a positive or negative relation with local control. 
There is some evidence for Ki-67/proliferation towards better local control (Table 1). 
Interestingly, two well-known markers in HNSCC; EGFR and P53, showed consistent 
evidence for not being predictive of local control after primary radiotherapy. 
 
Overall completeness, quality and applicability of evidence 
An extensive search has been performed to identify all published markers for local 
control after radiotherapy in laryngeal cancer. As found in this systematic review 
study quality varies among studies; almost all studies are retrospective cohorts, some 
do not report details on radiotherapy schedule, or outcome chosen, while others 
inadequately describe the interpretation of the assay used for detection of the 
biological tumor marker. In 2005 the REMARK criteria were published to encourage 
transparent and complete reporting in prognostic marker studies.
4
 However, also after 
introduction of REMARK, prognostic biological marker studies are still poorly 
reported.
59
 Remarkably, studies included in this systematic review did have a slightly 
better quality after 2006 than before. Adequate reporting is essential for drawing 
conclusions from a systematic review and should be emphasized for new publications.  
Despite the fact that this systematic review included studies on relatively 
homogeneous patient populations (e.g. only laryngeal cancer; only patients treated 
with primary radiotherapy) it was still difficult to compare studies analyzing the same 
biological tumor marker, because of multiple factors. First, most studies used small, 
heterogeneous patient populations. Some studies include both glottic and supraglottic 
tumors, others evaluate those separately, with sometimes different outcomes. For 
example, pFADD positivity was associated with better local control in glottic, but not 
in supraglottic laryngeal cancer patients.
37,38
 Glottic and supraglottic tumors often 
present with different symptoms, at different stages.
60-62
 Therefore supra- and glottic 
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radiotherapeutically treated patients, different treatment schedules (conventional vs. 
accelerated) could have influenced the results, as for Ki-67 and EGFR. Furthermore, 
the number of patients is low (median number of patients is 60) and a rationale for the 
number of included patients is not given. There are differences in methodology, such 
as different antibodies used, different cut-offs used for a marker, often without giving 
a rationale for the cut-off used. Finally, different definitions of outcome after 
radiotherapy are used such a local recurrence within 6 months while others use local 
recurrence within 5 years, where can be discussed if a local recurrence after 5 years 
should be considered as a recurrence or as a second primary tumor.  
 
Potential biases in review 
The most important potential bias in this review is publication bias; especially 
research with negative results might have not been published.  
 
Comparison with other reviews 
Also for other tumor sides there is no consistent evidence for the predictive value of 
Ki-67 for radiation response, though Ki-67 positivity is likely to be a poor prognostic 
factor for breast and cervical cancer, irrespectively of treatment modality.
63,64
  
A review by Bossi et al., shows the same results for EGFR in other HNSCC 
tumor sites.
65
 However, a relation with EGFR positivity and poor outcome after 
primary radiotherapy was found in some large groups of HNSCC patient treated with 
an accelerated radiotherapy schedule.
65
  
Previous p53 research showed p53 mutations as predictor of poor local control 
after primary radiotherapy in a variety of tumor sites, including HNSCC.
66
 A potential 
reason that we did not find a relation might be that in the studies included in our 
analysis, p53 was mostly studied by immunohistochemistry, not by mutational 
analysis. Research has shown that immunohistochemical staining is not always 
strongly correlated with mutational status, but optimization, standardization and 




Implications for clinical practice and research 
Biological tumor markers that are strongly predictive of response to primary 









 This article is protected by copyright. All rights reserved 
intensified) treatment or alternative treatment modalities such as surgery. Biological 
tumor markers could also contribute to identify new potential targets for therapeutic 
intervention. We found some evidence for Ki-67/proliferation being predictive of 
better local control after primary radiotherapy, whereas EGFR and P53 showed 
consistent evidence for not being predictive of local control after primary 
radiotherapy. Cell proliferation is one of the most essential biological processes in 
oncogenesis.
68
 Ki-67 is present in all the active phases of the cell cycle (G1, G2, M, 
mitosis), but absent in resting cells (G0),
69
 suggesting a role for Ki-67 as a potential 
predictor of outcome after radiotherapy, as radiotherapy affects dividing cells. 
However, the predictive value of Ki-67 for response to primary radiotherapy in 
laryngeal cancer is currently unclear and Ki-67 assessment methods lack 
standardization, thereby preventing clinical implementation. More research in well-
defined study populations is needed to elucidate the potential predictive role of Ki-67 
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Figure legends 
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Table 1 Proliferation markers in relation to outcome after primary radiotherapy in laryngeal cancer patients 
Author 
Year 

































OR per 10% 
increase, nuclear 







Ki-67 IHC >50% 
Continuous, nuclear 







Ki-67 IHC >10% nuclear 
 
Continuous, nuclear 
24 T1-2 Glottic RT Persistence or local 
recurrence 


















Ki-67 IHC >20% nuclear 21 T1-2N0 Glottic RT Local recurrence <1 yrs = 1.94 (0.32-
11.8)* 
 











































PCNA IHC Continuous, nuclear 28 T1N0 Glottic RT Recurrent or persistent, n.s. ↑  
* = (Subgroup) analysis performed by authors of this systematic review;  
↓ = Positivity of marker associated with poor outcome;  
↑ = Positivity of marker associated with good outcome;  
‘=’ = No relation with outcome;  
IHC = immunohistochemistry;  
TMA = tissue microarray;  
HR = Hazard ratio;  
OR = Odds ratio;  
CI = Confidence interval; 
n.s. = not specified  
RT = conventional radiotherapy;  
ART = accelerated radiotherapy;  
















- Other tumor site/histology n=102
- No primary radiotherapy n=67
- Marker not studied in primary tumor tissue n=14
- No biological marker n=85
- Other outcome n=0
- Cell line/xenograft studies n=33
- Reviews, case-reports, other n=74













- Other tumor site/histology n=14
- No primary radiotherapy n=54
- Marker not studied in primary tumor tissue n=7
- No biological marker n=3
- Other outcome n=14
- Cell line/xenograft studies n=10
- Reviews, case-reports, other n=16
Exclusion n=106
- Other tumor site/histology n=17
- No primary radiotherapy n=70
- Marker not studied in primary tumor tissue n=3
- No biological marker n=1
- Other outcome n=8
- Cell line/xenograft studies n=0
- Reviews, case-reports, other n=7
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